• Verana Networks

  Led · Series B · Apr 2022

  Verana Networks builds a purpose-built, software-defined 5G RAN platform aimed at service providers and enterprises with access to licensed millimeter wave spectrum. The company is designing hardware and software optimized for dense outdoor small cell deployments. Led by CEO Vedat Eyuboglu, Verana is commercializing new 5G technology from the ground up. The company plans to use recent funding to commercialize its mmWave RAN technology and expand R&D, marketing, sales, and technical services teams. Since its founding in April 2020, Verana has grown to over 70 employees across the United States and India. Verana Networks is developing a 5G radio access network (RAN) solution aimed at cutting the cost of building mmWave 5G networks by up to 10X. Its patent-pending network design supports 3GPP 5G New Radio (5G‑NR) specifications and Open RAN Alliance (O‑RAN) interfaces. The company targets mobile operators, enabling gigabit 5G for smartphones and 5G-based fixed wireless access. Verana emphasizes a customer-centric design that addresses costs across silicon, antennas, backhaul, and site permitting. Founders Vedat Eyuboglu and Amit Jain bring prior RAN product experience from Airvana and SpiderCloud Wireless, with previous deployments by large mobile operators. The company says it will use the Series A funding to build a team with deep RAN design and development expertise. Verana is based in Waltham, Mass.

• Kandou AI

  Participated · Series D · Dec 2021

  Kandou AI designs and delivers high-performance connectivity products and interconnect IP for datacenter infrastructure, AI and consumer electronics customers. The company reports over 20 million silicon units shipped using its technology. Recent engineering milestones include tapeout of its next-generation SerDes technology and growing momentum in its retimer product lines. Kandou AI has expanded its global engineering footprint with a new design center in Hyderabad, India, and has added industry veterans to its executive team. With the $225M Series A, the company plans manufacturing ramp-up for its AI connectivity chips and to accelerate its chip and IP portfolio. The company is led by Co-Founder and CEO Srujan Linga and is headquartered in Saint-Sulpice, Switzerland.

• Werewolf Therapeutics

  Participated · Series B · Jan 2021

  Werewolf Therapeutics advances a pipeline of INDUKINE™ molecules, a novel class of systemically delivered, conditionally activated proinflammatory immune modulators. The company uses its proprietary PREDATOR™ protein engineering platform to create therapeutics that are inactive in circulation and selectively activated within the tumor microenvironment. Its lead candidates, WTX-124 (IL-2) and WTX-330 (IL-12), aim to deliver full cytokine potency in tumors while minimizing off-target toxicities that limit systemic cytokine therapies. Preclinical studies reportedly showed anti-tumor activity and favorable pharmacokinetic and safety profiles. Werewolf plans to advance its lead programs into Phase 1 clinical proof-of-concept studies and to progress additional programs to IND-readiness using proceeds from the financing. The company is building its team for clinical development, including recent appointments of Randi Isaacs as Chief Medical Officer and Ellen Lubman as Chief Business Officer. Werewolf Therapeutics is a Cambridge, Mass.-based oncology biotherapeutics company advancing a pipeline of cancer treatments built on its PREDATOR™ protein engineering platform. The platform produces biologics that can be systemically delivered in an inactivated format and are selectively activated within the tumor microenvironment to unleash cytokines and immune stimulatory antibodies. Initial drug development efforts focus on INDUKINESTM, conditionally activated cytokines designed to safely and effectively deliver potent antitumor immunity. The company is led by President and CEO Daniel J. Hicklin, Ph.D., with co-founder Luke Evnin, Ph.D. serving as Chairman. Werewolf plans to use the financing to invest in research, talent acquisition and to advance its platform and therapeutic programs toward early clinical development. The company completed a $56M Series A financing to support these efforts.

No current team members are available.